Invitae Accelerates Personalized Oncology Testing With Genosity Acquisition
Published
Apr 05 2021 at 1:29 PM GMT
Key
Points
Points
- Invitae Corp (NYSE: NVTA) has agreed to acquire Genosity Inc, a genomics company offering software and laboratory solutions to enable the development and deployment of complex sequencing-based tests.
- Deal consideration of approximately $200 million includes roughly $120 million in cash and roughly $80 million in Invitae common stock.
- Invitae is currently developing its Personalized Cancer.
Tags
Trending
Stats
- Published Apr 5, 2021 1:29 PM GMT